scholarly journals Response to safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience

2018 ◽  
Vol 256 (11) ◽  
pp. 2271-2271 ◽  
Author(s):  
Julie Blanc ◽  
Laurent Kodjikian ◽  
Alain Bron ◽  
Catherine Creuzot-Garcher
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Cystoid Macular Edema ◽  
Dexamethasone Intravitreal Implant ◽  
Term Efficacy ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Intravitreal Implant

scholarly journals Intraocular Pressure Control for Patients Undergoing Combination Intravitreal Anti-VEGF and Dexamethasone Therapy for Macular Edema from Retinal Vein Occlusion

2018 ◽  
Vol 4 (1) ◽  
pp. 234-237
Author(s):  
Michael Singer ◽  
Darren Bell ◽  
Joshua Singer ◽  
Paul Woods ◽  
Tyson R. Jergensen ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Sustained Release ◽  
Macular Edema ◽  
Ocular Hypertension ◽  
Retinal Vein Occlusion ◽  
Retrospective Chart Review ◽  
Dexamethasone Intravitreal Implant ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Intravitreal Implant

Background and Objective: Sustained-release dexamethasone intravitreal implant is an effective treatment for macular edema secondary to retinal vein occlusion (RVO) but ocular hypertension is a side effect. This study evaluated whether the addition of a single combination IOP-lowering medication will reliably control intraocular pressure (IOP) for those patients.   Study Design/Patients and Methods: Retrospective chart review of 62 patients that underwent multiple injections of combination anti-VEGF and sustained-release dexamethasone intravitreal implant for macular edema secondary to RVO. IOP spikes were treated with brimonidine 0.2% - timolol 0.5%. IRB approval was obtained.   Results: The average elevated IOP requiring treatment was 28.6 mmHg. The average IOP after adding brimonidine 0.2% - timolol 0.5% was 16.7 mmHg. 100 percent of treatment cycles had an IOP< 30 mmHg after starting treatment.   Conclusions: Using one combination IOP-lowering drop can reliably control the ocular hypertension that occurs secondary to combination therapy for macular edema in RVO.

Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion

Ophthalmology ◽  
2010 ◽  
Vol 117 (6) ◽  
pp. 1134-1146.e3 ◽  
Author(s):  
Julia A. Haller ◽  
Francesco Bandello ◽  
Rubens Belfort ◽  
Mark S. Blumenkranz ◽  
Mark Gillies ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Controlled Trial ◽  
Dexamethasone Intravitreal Implant ◽  
Vein Occlusion ◽  
Intravitreal Implant
Sign in / Sign up

Export Citation Format

Share Document